XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.21.1

Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
Schedule of Derivative Liabilities at Fair Value | The following table presents the changes in the development derivative liability from inception on February 12, 2021 to March 31, 2021:
|  | Three Months Ended March 31, 2021
Fair value at inception on February 12, 2021 |  | $ | — |
Non-cash research and development expense |  | 2,248 |
Cash receipts from SFJ |  | 750 |
Change in the fair value of development derivative liability |  | 1,599 |
Fair value at March 31, 2021 |  | $ | 4,597 |

X
- References No definition available. + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration